Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


Gus Bassani Joins Imprimis Board Of Directors
New Director Brings Extensive Experience in Pharmaceutical Compounding and Drug Development, and Knowledge of Market Needs, to His New Role

SOLANA BEACH, Calif., Dec. 18, 2012 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY: OTCQB) today announced that Gus Bassani, Pharm. D., Vice President of Consulting, R&D and Formulations with the Professional Compounding Centers of America, Inc. (PCCA), will join its board of directors.

Imprimis Pharmaceuticals is dedicated to improving patient health and quality of life by leveraging a patented topical drug delivery platform that enables highly targeted site specific treatment.  Its lead drug candidate, Impracor, utilizes the company's innovative Accudel cream formulation to deliver ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), to target underlying tissue where Impracor exerts its localized anti-inflammatory effect.

Bassani has been with PCCA since September 2002.  Prior to that, he was a formulation pharmacist in the product development lab of a veterinary pharmaceutical company.  He has worked in multiple pharmacy practice settings, located in Alaska, Iowa and Kansas, and has taught extemporaneous compounding principles to pharmacy students in Drake University's Pharmaceutics Laboratory course.

Compounding pharmacists work to solve problems for specific patients by devising alternative drug formulations and delivery platforms, an area where Bassani has extensive experience interacting with thousands of pharmacists around the world.

"We are very pleased to welcome Gus Bassani to the Imprimis team," said Mark L. Baum, Imprimis CEO.  "He will provide invaluable assistance and insight as we bring our lead drug to market, and explore potential applications and markets for our patented drug delivery platform."

"I'm very excited to be part of the Imprimis board, and in a position to help guide drug development and future projects," Bassani said.  "I believe my experience in pharmaceutical compounding, drug formulation and research and development will serve as an asset as Imprimis moves forward."

In addition to his role with PCCA, Bassani sits on the United States Pharmacopeia Council of Experts, a body that writes standards for the pharmaceutical industry.  His term on the council runs through 2015.

Bassani will be the sixth member of the Imprimis board of directors.  The board also includes Mark L. Baum, Robert Kammer, Jeff Abrams, Paul Finnegan and Stephen G. Austin.

About Imprimis Pharmaceuticals, Inc.

Imprimis Pharmaceuticals is a specialty pharmaceutical company developing non-invasive, topically delivered products. Our innovative patented Accudel cream formulation technology is designed to enable highly targeted site-specific treatment. Impracor, our lead pain product candidate, utilizes the Accudel platform technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug, through the skin directly into the underlying tissues where the drug exerts its localized anti-inflammatory and analgesic effects. We intend to leverage the Accudel platform technology to expand and create a portfolio of topical products for a variety of indications.  For more information, visit http://imprimispharma.com/.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products and to enter into strategic alliances and transactions, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no  obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Contact: Mark L. Baum
Imprimis Pharmaceuticals, Inc.
(858) 433-2800

SOURCE Imprimis Pharmaceuticals, Inc.

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Web 2.0 Latest News
A few weeks back, I wrote a post about getting ready to address a coworker's bad code. This sparked some conversation across various media, including the following interesting question: ...seems that there is a breakdown in managing the development process. Why is Bob allowed [to kee...
Tune into: a cloud mindset One of the tenets of the cloud religion is that it should be possible – through the use of intelligent software – to build reliable systems on top of unreliable hardware. Just like you can build reliable and affordable storage systems using RAID (...
DevOps has traditionally played important roles in development and IT operations, but the practice is quickly becoming core to other business functions such as customer success, business intelligence, and marketing analytics. Modern marketers today are driven by data and rely on many ...
Listen closely to the background hum of any agile shop, and you'll likely hear this ongoing chant: Automate! Automate! Automate! While automation can be incredibly valuable to the agile process, there are some key things to keep in mind when it comes to automated performance testing. ...
Developers are – despite their attention to what is considered a very logic-based field of study – a very creative group. Give them a hurdle to overcome and they will. The problem, of course, is not that they’ve solved a problem, it’s that in doing so they’ve likely created a source of...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE